Loading...

Inventiva S.A.

0RNK.L•LSE
Healthcare
Medical - Pharmaceuticals
£2.78
£0.11(4.12%)

Inventiva S.A. (0RNK.L) Stock Overview

Explore Inventiva S.A.’s financial performance, market position, analyst ratings, and future outlook.

Meyka AI Score

B

Score: 65.1/100

Key Financials

Market Cap384.6M
P/E Ratio-1.02
EPS (TTM)$-1.27
ROE1.98%
Fundamental Analysis

AI Price Forecasts

1 Week$2.98
1 Month$2.45
3 Months$1.37
1 Year Target$2.10

0RNK.L Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of Inventiva S.A. (0RNK.L) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

The current technical analysis reveals key indicators including an RSI of 48.56, suggesting the stock is in a neutral condition. Our forecasting models predict significant price movements, with a 12-month target of $2.10.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -1.02 and a market capitalization of 384.6M. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

Technical Indicators

48.56RSI (14)
-0.05MACD
17.88ADX
Stats data is not available for 0RNK.LStats details for 0RNK.L are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.
Analyst Recommendations data is not available for 0RNK.LAnalyst Recommendations details for 0RNK.L are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Company Profile

Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS), and other diseases. Its lead product candidate is Lanifibranor, which has completed Phase IIb clinical trial to treat NASH. The company also develops Odiparcil, which has completed Phase IIa clinical trial for the treatment of MPS VI subtype disease. In addition, it has a pipeline of earlier stage programs in oncology and other diseases. The company has strategic collaboration with AbbVie for the treatment of autoimmune diseases; and Boehringer Ingelheim International GmbH for developing new treatments for idiopathic pulmonary fibrosis. Inventiva S.A. was founded in 2011 and is based in Daix, France.

CEO

Frederic Cren

Employees

114

Headquarters

50 rue de Dijon, Daix

Founded

2017

Frequently Asked Questions

;